<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074970</url>
  </required_header>
  <id_info>
    <org_study_id>BRE09-146</org_study_id>
    <nct_id>NCT01074970</nct_id>
  </id_info>
  <brief_title>PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations</brief_title>
  <official_title>PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate 2-year disease-free survival in this patient&#xD;
      population treated with single agent cisplatin and patients treated with cisplatin in&#xD;
      combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability&#xD;
      of this treatment in patients with residual disease following preoperative chemotherapy will&#xD;
      also be observed and characterized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort&#xD;
      2). Patients in the safety run will be included in the efficacy analysis on intent to treat&#xD;
      basis:&#xD;
&#xD;
      Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg IV D 1,2,3 every 3&#xD;
      weeks x 4 cycles&#xD;
&#xD;
      If cycle 1 is well tolerated, the dose of Rucaparib will be escalated from 16 mg to 24 mg for&#xD;
      subsequent cycles in the cohort 1, and 24 mg to 30 mg in the cohort 2.&#xD;
&#xD;
      If ≤ 1 of 6 patients in cohort 1 experiences DLT, cohort 2 will commence. If 2 or more of 6&#xD;
      patients in cohort 1 experience DLT, the study will be suspended and an amendment to explore&#xD;
      lower doses will be considered.&#xD;
&#xD;
      If ≤ 1 of 6 patients in cohort 2 experiences DLT, the randomized portion of the study will&#xD;
      commence. If 2 or more of 6 patients experience DLT, the study will be suspended and an&#xD;
      amendment to proceed with the randomized portion at the cohort 2 dose (24 mg) will be&#xD;
      considered.&#xD;
&#xD;
      During the randomized portion of the study, patients will be randomized to either Arm A or&#xD;
      Arm B.&#xD;
&#xD;
      Stratification factors:&#xD;
&#xD;
        -  Anthracycline vs. not&#xD;
&#xD;
        -  Residual LN involvement vs. No Residual LN involvement&#xD;
&#xD;
      Arm A (Cisplatin Monotherapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles&#xD;
&#xD;
      Arm B (Combination Therapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib&#xD;
      16-30 mg IV D1,2,3 every 3 weeks x 4 cycles&#xD;
&#xD;
      Rucaparib maintenance 30 mg IV weekly x 24 weeks&#xD;
&#xD;
      ECOG Performance Status 0-1&#xD;
&#xD;
      Life Expectancy: Not Specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  Hemoglobin (Hgb) &gt; 9.0 g/dL&#xD;
&#xD;
        -  Platelets &gt; 100 K/ mm3&#xD;
&#xD;
        -  Absolute neutrophil count (ANC) &gt; 1.5 K/mm3&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Bilirubin &lt; upper limit of normal (except in patients with documented Gilbert's disease,&#xD;
           who must have a total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
        -  Aspartate aminotransferase (AST, SGOT) &lt; 2.5 x ULN&#xD;
&#xD;
        -  Alanine aminotransferase (ALT, SGPT) &lt; 2.5 x ULN&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Calculated creatinine clearance of &gt; 50 cc/min using the Cockcroft-Gault formula&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  Left ventricular ejection fraction within normal limits.&#xD;
&#xD;
        -  Patients with an unstable angina or myocardial infarction within 12 months of study&#xD;
           entry are excluded.&#xD;
&#xD;
        -  No clinically significant arrhythmia or baseline ECG abnormalities in the opinion of the&#xD;
           treating investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year Disease Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate 2-year disease-free survival (DFS), in patients with confirmed TNBC or ER/PR + HER2-, known BRCA1/2 mutations treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects and Tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>To characterize the side effects and tolerability of cisplatin and cisplatin plus Rucaparib in patients with residual disease following preoperative chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Disease Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate 1-year DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>60 months</time_frame>
    <description>To determine 5-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Data</measure>
    <time_frame>12 months</time_frame>
    <description>To collect limited pharmacokinetic data, in patients receiving study drug to compliment ongoing PK analyses in other trials with Rucaparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen Collection</measure>
    <time_frame>12 months</time_frame>
    <description>To collect peripheral blood lymphocytes, archived tumor specimens, and genomic DNA to explore potential correlates of PARP inhibition, recurrence and toxicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Cisplatin Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Combination Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles&#xD;
Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles</description>
    <arm_group_label>Arm A: Cisplatin Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles</description>
    <arm_group_label>Arm B: Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles</description>
    <arm_group_label>Arm B: Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-)&#xD;
             invasive breast cancer, stage I-III at diagnosis (AJCC 6th edition) based on initial&#xD;
             evaluation by clinical examination and/or breast imaging. NOTE: Patients with ER+&#xD;
             and/or PR+ may enroll ONLY if they are known carriers of a deleterious mutation in&#xD;
             BRCA1 or BRCA2. Patients with HER2+ tumors may not enroll regardless of BRCA status.&#xD;
&#xD;
          -  Must have completed preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable&#xD;
             preoperative regimens include an anthracycline or a taxane, or both. Patients may NOT&#xD;
             have received cisplatin as part of their neoadjuvant therapy regimen. Patients who&#xD;
             received preoperative therapy as part of a clinical trial may enroll. No adjuvant&#xD;
             chemotherapy after surgery other than that specified in this protocol is allowed.&#xD;
             Adjuvant bisphosphonate use is allowed.&#xD;
&#xD;
          -  Must have completed definitive resection of primary tumor. The last surgery for breast&#xD;
             cancer must have been completed at least 14 days prior to registration for protocol&#xD;
             therapy.&#xD;
&#xD;
          -  Must have significant residual invasive disease at the time of definitive surgery&#xD;
             following preoperative chemotherapy. Significant residual disease is defined at least&#xD;
             one of the following:&#xD;
&#xD;
               -  Miller-Payne response in the breast of 0-25.&#xD;
&#xD;
               -  Residual Cancer Burden (RBC) classification II or III6&#xD;
&#xD;
               -  Residual carcinoma in one or more regional lymph nodes that would meet AJCC 6th&#xD;
                  edition criteria for N1 - N3 disease.&#xD;
&#xD;
               -  Alternatively, if Miller-Payne or RCB grading is not available, the patient will&#xD;
                  be eligible if the pathology report indicates that the area of residual invasive&#xD;
                  disease in the breast measures at least 2 cm following preoperative therapy. The&#xD;
                  presence of DCIS without invasion does not qualify as residual disease in the&#xD;
                  breast.&#xD;
&#xD;
          -  Whole breast radiotherapy is required for patients who underwent breast conserving&#xD;
             therapy, including lumpectomy or partial mastectomy. Patients receiving adjuvant&#xD;
             radiation therapy must have completed radiotherapy at least 14 days prior to&#xD;
             registration for protocol therapy.&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information.&#xD;
&#xD;
          -  Age &gt; 18 years at the time of consent.&#xD;
&#xD;
          -  Must consent to allow submission of archived tumor tissue sample from definitive&#xD;
             surgery.&#xD;
&#xD;
          -  Must consent to collection of blood samples for PK analysis.&#xD;
&#xD;
          -  Women of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception from the time consent is signed until 4 weeks after treatment&#xD;
             discontinuation.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test within 14 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
          -  Women must not be breastfeeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No stage IV (metastatic) disease, however no specific staging studies are required in&#xD;
             the absence of symptoms or physical exam findings that would suggest distant disease.&#xD;
&#xD;
          -  No treatment with any investigational agent within 30 days prior to registration for&#xD;
             protocol therapy.&#xD;
&#xD;
          -  No history of chronic hepatitis B or C&#xD;
&#xD;
          -  No clinically significant infections as judged by the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy D. Miller, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute Breast Cancer Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc./IU Health Arnett</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Medical Associates</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Cancer Care</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer &amp; Hematologic Disease</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virtua Health Cancer Program</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Health Care</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Group</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center: Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE a Women's Cancer Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Fox Chase Regional Cancer Center</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bux-Mont Oncology Hematology Associates (FCCC) at Grand View Hospital</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosiercancer.org</url>
    <description>Hoosier Cancer Research Network Homepage</description>
  </link>
  <reference>
    <citation>S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge, K. Miller. PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier oncology group BRE09-146. J Clin Oncol 29: 2011 (suppl; abstr TPS130)</citation>
  </reference>
  <reference>
    <citation>S. Dwadasi, Y. Tong, T. Walsh, M.A. Danso, C.X. Ma, P.A Silverman, M.C. King, S.M. Perkins, S.S. Badve, K. Miller. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Oncology Group BRE09-146. J Clin Oncol 32:5s, 2014 (suppl; abstr 1019^)</citation>
  </reference>
  <results_reference>
    <citation>Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082)</citation>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibition + breast cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>Triple negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 16, 2020</submitted>
    <returned>November 6, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

